Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Acta Pharmaceutica Sinica B · 2023-02 · 13 (2) · 498-516
DOI: 10.1016/j.apsb.2022.07.020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-02. Verfasst von Chen Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang 110122, China.
- Liaoning Medical Diagnosis and Treatment Center, Shenyang 110000, China.
- Department of Digestive Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2023). Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta Pharmaceutica Sinica B, 13(2), 498-516. https://doi.org/10.1016/j.apsb.2022.07.020
Vancouver
Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta Pharmaceutica Sinica B. 2023;13(2):498-516. doi:10.1016/j.apsb.2022.07.020
BibTeX
@article{Fu2023,
author = {Fu, Chen and Yu, Lifeng and Miao, Yuxi and Liu, Xinli and Yu, Zhaojin and Wei, Minjie},
title = {Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {2},
pages = {498--516},
doi = {10.1016/j.apsb.2022.07.020}
}
EUVIMED